GSK1904529A is a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) and insulin receptor (IR). It is currently being studied as a potential treatment for various types of cancers, including breast cancer and lung cancer. GSK1904529A was first developed by GlaxoSmithKline and has undergone several clinical trials.
The chemical name of GSK1904529A is N-(4-(3-amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorophenyl)-5-chloro-4-(2-methylpropoxy)pyridine-3-carboxamide.
The molecular formula of GSK1904529A is C24H21ClFN7O2.
The formula weight of GSK1904529A is 495.92 g/mol.
The CAS number of GSK1904529A is 1089283-49-7.
Top Ten Keywords from Google and Synonyms
Synonyms: GSK-529, GSK529, N-(4-(3-Amino-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-2-fluorophenyl)-5-chloro-4-(2-methylpropoxy)nicotinamide
Health Benefits of GSK1904529A
GSK1904529A has shown promising results in treating various types of cancers, particularly breast cancer and lung cancer. By inhibiting both IGF-1R and IR, it works to slow or stop the growth and spread of cancer cells.
Clinical studies have shown that GSK1904529A can effectively treat breast cancer and lung cancer. In one phase I study, researchers found that GSK1904529A was well-tolerated and showed signs of efficacy in patients with advanced solid tumors who had previously received other treatments.
GSK1904529A works by specifically targeting both IGF-1R and IR, two proteins that are often overexpressed in cancer cells and play a critical role in regulating cell growth and survival. By inhibiting these proteins, GSK1904529A suppresses the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression.
GSK1904529A has generally been well-tolerated in clinical trials. However, like all medications, it can cause side effects. Common side effects include fatigue, nausea, vomiting, and diarrhea. More severe side effects may occur in some patients, such as liver damage or allergic reactions. Patients should be closely monitored for any adverse reactions while taking GSK1904529A.
The most common side effects of GSK1904529A include:
More severe side effects may occur in some patients, such as:
The dosing of GSK1904529A depends on the type of cancer being treated and other individual factors. It is typically administered orally in tablet form, either alone or in combination with other cancer therapies. The recommended dose varies depending on the clinical trial or physician's discretion.
In conclusion, GSK1904529A is a promising drug candidate for cancer therapy, particularly in the treatment of various types of cancers, including breast cancer and lung cancer. As an inhibitor of both IGF-1R and IR, it shows potential in suppressing the signaling pathways that are critical for cancer cell growth and survival, thereby slowing down or stopping cancer progression. While further clinical trials are needed to determine its efficacy and safety, GSK1904529A represents an important step towards precision medicine and molecular targeted therapy in cancer treatment